Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | KIT | P10721 | 2/20 | 0.37 |
| ▸ | MTOR | P42345 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | AXL | P30530 | 2/20 | 0.35 |
| ▸ | MERTK | Q12866 | 2/20 | 0.35 |
| ▸ | NEK2 | P51955 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL428163 | 0.91 | FAAH (0.48) | FAAHCES2NPC1RAB9APDE4B | |
| SCHEMBL424691 | 0.90 | FAAH (0.56) | FAAHCES2NPC1NEK2PDE4B | |
| SCHEMBL14950293 | 0.89 | FAAH (0.46) | FAAHCES2NPC1RAB9APIK3CD | |
| SCHEMBL427345 | 0.88 | FAAH (0.46) | FAAHCES2NPC1RAB9AMTOR | |
| SCHEMBL427328 | 0.88 | FAAH (0.46) | FAAHCES2KITPIK3CANEK2 | |
| SCHEMBL7899710 | 0.87 | FAAH (0.48) | FAAHCES2PIK3CDMTORPIK3CA | |
| SCHEMBL427411 | 0.86 | FAAH (0.48) | FAAHCES2NPC1RAB9APIK3CD | |
| SCHEMBL14937556 | 0.86 | FAAH (0.46) | FAAHCES2NPC1RAB9APIK3CD | |
| SCHEMBL14937905 | 0.86 | TBK1 (0.45) | FAAHCES2NPC1RAB9AMTOR | |
| SCHEMBL426156 | 0.86 | FAAH (0.50) | FAAHCES2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9353082-B2 | Pharmaceutical compounds | BIAL—PORTELA & CA, S.A. (PT) | 2016-05-31 | — | — | US | disclosed |
| US-9353082-B2 | Pharmaceutical compounds | BIAL—PORTELA & CA, S.A. (PT) | 2016-05-31 | — | — | US | disclosed |
| US-20120065191-A1 | PHARMACEUTICAL COMPOUNDS | BIAL - PORTELA & Cª, S.A. (PT) | 2012-03-15 | — | — | US | disclosed |
| US-20120065191-A1 | PHARMACEUTICAL COMPOUNDS | BIAL - PORTELA & Cª, S.A. (PT) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065191-A1 | PHARMACEUTICAL COMPOUNDS | FAAH, FAAH2, ASAH1 | FAAH 1/4885CES2 62/4885NPC1 446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.